Phase 2 Tuberculosis Trial, Recruiting NCT06477185 Sponsor: Makerere University Condition: Tuberculosis
Back to Tuberculosis

Phase 2 Tuberculosis Trial, Recruiting

NCT06477185
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You have been diagnosed with a current episode of pulmonary tuberculosis (TB in the lungs), confirmed by a sputum test or a GeneXpert test showing the TB is not resistant to the antibiotic rifampicin
  • Your chest X-ray shows TB affecting a significant portion of both lungs (at least 30% of the lungs), classed as moderate or advanced TB
  • You do not have HIV
  • You are willing and able to attend scheduled appointments, follow the treatment plan, and complete required tests and procedures
  • You are able to read and sign a consent form agreeing to take part

Who may not be able to join:

  • You are currently pregnant
  • You are currently breastfeeding
  • Your kidney or liver test results are significantly above the normal range (more than twice the upper normal level)
  • You have been taking steroid medications for 14 days or more, or have already been taking TB treatment for more than 7 days
  • You are already taking part in another clinical trial
  • You have diabetes, or have previously taken or are currently taking the medication metformin
  • You have been diagnosed with cancer, or are currently taking cancer treatment
  • You are taking any medication that is known to interact with the trial drug
  • You have a known allergy to doxycycline or similar antibiotics (tetracyclines)
  • You have a known autoimmune disease (a condition where your immune system attacks your own body)
  • You have any other health factor that the trial team believes could significantly increase your risk of side effects (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0782303377

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Makerere University
Registry
ClinicalTrials.gov
Start date
4 December 2024
Est. completion
20 December 2026

Where this trial is recruiting

Uganda

Primary endpoints

Mean High resolution CT (HRCT) fibrosis scores; Efficacy of doxycycline as an anti-TB associated fibrosis agent

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov